Mitochondrial injury. Lessons from the fialuridine trial

Drug Safety

Volumn 17, Issue 1, 1997, Pages 1-7

  Honfcoop, Pieter ^a   Scholte, Hans R ^a   De Man, Robert A ^a   Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DIDANOSINE; FAMCICLOVIR; FIALURIDINE; GANCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PYRUVIC ACID; RIBAVIRIN; VIDARABINE; ZALCITABINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CELL DAMAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HEPATITIS B; HUMAN; LACTIC ACIDOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; META ANALYSIS; MITOCHONDRION; MULTIPLE ORGAN FAILURE; MYALGIA; MYOPATHY; NAUSEA; NEUROPATHY; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; PANCREATITIS; PARESTHESIA; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; VOMITING;

EID: 8544249855     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717010-00001     Document Type: Review

References (37)

1. Korba BE, Milman G. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res 1991; 15: 217-28
2. Fourel I, Hantz O, Watanabe KA, et al. Inhibitory effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 1990; 34: 473-5
3. Fried MW, Di Bisceglie AM, Straus SE, et al. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B [abstract]. Hepatology 1992; 16: 127A
4. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099-105
5. Kleiner DE, Gaffey MJ, Sallie R, et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 1997; 10: 192-9
6. Staschke KA, Colacino JM, Mabry TE, et al. The in vitro anti-hepatitis B virus activity of FIAU [1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl-5-iodo)-uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res 1994; 23: 45-61
7. Manning FJ, Swartz M. Review of the fialuridine (FIAU) clinical trials. Washington, DC: National Academy Press, 1995
8. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1: 417-22
9. Martin JL, Brown CE, Matthews-Davis N, et al. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38: 2743-9
10. Lewis W, Meyer RR, Simpson JF, et al. Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 1994; 33: 14620-4
11. Parker WB, Cheng YC. Mitochondrial toxicity of antiviral nucleoside analogs. J NIH Res 1994; 6: 57-61
12. Cherrington JM, Allen SJ, McKee BH, et al. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma. Biochem Pharmacol 1994; 48: 1986-8
13. Cui L, Yoon S, Schinazi RF, et al. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 1995; 95: 555-63
14. Colacino JM, Malcolm SK, Jaskunas SR. Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture. Antimicrob Agents Chemother 1994; 38: 1997-2002
15. Klecker RW, Katki AG, Collins JM. Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-2′-fluoro-2′-deoxy-beta-D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells. Mol Pharmacol 1994; 46: 1204-9
16. Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem 1985; 54: 1015-69
17. Walker JE. The NADH : ubiquinone oxidoreductase (Complex I) of respiratory chains. Q Rev Biophys 1992; 25: 253-324
18. Shoffner JM, Wallace DC. Oxidative phosphorylation diseases. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, Inc., 1995: 1535-609
19. Colacino JM. Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU). Antiviral Res 1996; 29: 125-39
20. Robinson BH, Ward J, Goodyer P, et al. Respiratory chain defects in the mitochondria of cultured skin fibroblasts from three patients with lacticacidemia. J Clin Invest 1986; 77: 1422-7
21. Wijburg FA, Feller N, Scholte HR, et al. Studies on the formation of lactate and pyruvate from glucose in cultured skin fibroblasts: implications for detection of respiratory chain defects. Biochem Int 1989; 19: 563-70
22. Chariot P, Gherardi R. Partial cytochrome c oxidase deficiency and cytoplasmic bodies in patients with zidovudine myopathy. Neuromuscul Disord 1991; 1: 357-63
23. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-10
24. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322: 1098-105
25. Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989; 264: 11934-7
26. Lai KK, Gang DL, Zawacki JK, et al. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Ann Intern Med 1991; 115: 283-4
27. Shaw T, Amor P, Civitico G, et al. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994; 38: 719-23
28. Cirelli R, Herne K, McCrary M, et al. Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996; 29: 141-51
29. Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 1996; 40: 1282-4
30. Main J, Brown JL, Howells C, et al. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3: 211-5
31. Doong SL, Tsai CH, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495-9
32. de Man RA, Schalm SW, Main J, et al. A dose ranging study to determine the antiviral activity and safety of lamivudine (2′-deoxy-3′-thiacytidine) in patients with chronic hepatitis B infection [abstract]. Gut 1993; 34: S5
33. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-61
34. Honkoop P, de Man RA, Scholte HR, et al. Effect of lamivudine treatment on morphology and function of the mitochondrial system in patients with chronic hepatitis B. Hepatology. In press
35. Kruining J, Heijtink RA, Schalm SW. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J Hepatol 1995; 22: 263-7
36. Robinson BH, McKay N, Goodyer P, et al. Defective intra-mitochondrial NADH oxidation in skin fibroblasts from an infant with fatal neonatal lacticacidemia. Am J Hum Genet 1985; 37: 938-46
37. Wanders RJA, Ruiter JPN, Wijburg FA. Studies on mitochondrial oxidative phosphorylation in permeabilized human skin fibroblasts: application to mitochondrial encephalomyopathies. Biochim Biophys Acta 1993; 118: 219-22